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AbstrACt 
Introduction Little is known about the impact of bladder 
cancer (BC) and its treatments on health-related quality of 
life (HRQL). To date, most work has been small in scale or 
restricted to subsets of patients. Life and bladder cancer is 
a cross-sectional and longitudinal study collecting patient-
reported outcomes within two distinct cohorts.
Methods and analysis A longitudinal study will collect 
patient-reported outcomes at 3-monthly intervals from 
newly diagnosed patients. Eligible cases will be identified 
by recruiting hospitals and surveyed at baseline, 6, 9 and 
12 months postdiagnosis to explore changes in outcomes 
over time. A separate cross-sectional cohort of patients 
diagnosed within the last 10 years across Yorkshire 
will be identified through cancer registration systems 
and surveyed once to explore longer-term HRQL in BC 
survivors. A comprehensive patient-reported outcome 
measure (PROM) has been developed using generic, 
cancer-specific and BC-specific instruments. The study 
will provide evidence about how useful these PROMs are 
in measuring BC patient HRQL. The outcome data will 
be linked with administrative health data (eg, treatment 
information from hospital data).
Ethics and dissemination The study has received the 
following approvals: Yorkshire and the Humber—South 
Yorkshire Research Ethics Committee (17/YH/0095), Health 
Research Authority Confidentiality Advisory Group (17/
CAG/0054). Results will be made available to patients, 
funders, NHS Trusts, Clinical Commissioning Groups, 
Strategic Clinical Networks and other researchers.
IntroduCtIon
Context
Bladder cancer (BC) is one of the most 
common human cancers and one of the most 
expensive to manage.1–3 Despite the cost of 
managing affected patients, BC receives a 
relatively low proportion of research and 
healthcare funding.
Most BCs are non-muscle invasive 
(NMIBC), which are managed by endoscopic 
resection with intravesical chemotherapy 
or immunotherapy and long-term surveil-
lance.4–6 Around one-third of tumours are 
aggressive, muscle-invasive tumours  (MIBC), 
requiring radical treatment.7 This radical 
treatment is usually radical cystectomy or 
radiotherapy, and includes treatment of adja-
cent viscera with regional lymph nodes, and 
often includes systemic chemotherapy. Infor-
mation about which treatments are associated 
with greater survival rates is lacking.
Survival data for BC is around 50% at 
5 years8. There are regional variations in 
service provision and outcomes, and patients 
with BC in Yorkshire have some of the lowest 
survival rates in the UK.9
Patient-reported outcome measures
As cancer survival has increased in the UK, 
the quality of that survival has become increas-
ingly important. Patients may experience 
short-term and long-term effects as a result 
of the cancer or cancer treatment, resulting 
in functional restrictions (eg, physical, 
emotional and social) or in specific symptoms 
(eg, urinary problems, fatigue, pain). These 
effects may impact on the everyday lives of 
individuals at home, at work, in relationships, 
recreationally and emotionally.
strengths and limitations of this study
 ► Patients with all stages and grades of bladder can-
cer (muscle invasive and non-muscle invasive) will 
be included in both studies.
 ► Cross-sectional survey data will be linked with avail-
able NHS data and longitudinal survey data will be 
linked with case report forms in order to optimise 
the levels of clinical and treatment information.
 ► Patient-reported outcome measures data will be 
used to understand differences between newly di-
agnosed patients, those undergoing treatment and 
those having completed treatment and compare dif-
ferent treatments and healthcare providers.
 ► Recruitment and retention of patients may be a chal-
lenge; particularly those from more deprived areas.
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Patient-reported outcome measures (PROMs) seek 
to ascertain patients’ views of their symptoms, their 
functional status and health-related quality of life 
(HRQL).10 Studies using PROMs are being pursued in 
England to improve patient care by assisting clinicians 
to provide better and more patient-centred care, and 
providing data for evaluating practices and policies.10
Policy
The collection and reporting of PROMs is a key priority 
as set out in the Government’s July 2010 White Paper, 
Equity and Excellence: Liberating the NHS, where 
the commitment was made to ‘extend PROMs across 
the NHS wherever practicable’.11 In order to improve 
understanding of the quality of life outcomes for 
cancer survivors, the National Cancer Survivorship 
Initiative developed a national survey of cancer survi-
vors.12 Robust collection of PROMs was perceived as 
central to health service reforms in the UK and essen-
tial for the improvement of cancer outcomes through 
the provision of evidence for domains 2 and 3 of the 
new English health framework; enhancing HRQL of 
individuals with long-term conditions and enhancing 
recovery from ill-health, respectively.13 Hence, the 
development and delivery of evidence-based PROMs 
surveys was pivotal to current national health policy. 
The National Cancer PROMs programme was estab-
lished and developed methodology for popula-
tion-based PROMs surveys.14 Subsequent national 
roll-out included evaluation of all individuals’ postco-
lorectal cancer diagnosis.15 In addition to this, head 
and neck cancer PROMs research has recently been 
published16 17 and a current study is measuring PROMs 
in British prostate cancer patients, as part of a Pros-
tate Cancer UK/Movember survey (life after prostate 
cancer diagnosis (LAPCD)).18
The life and bladder cancer (LABC) study will deliver 
evidence framed in terms of current health policy, 
thereby supporting health and social care organisations 
to recognise and develop programmes to address unmet 
needs and maximise HRQL for patients living with and 
beyond BC.
Current knowledge
Literature suggests that two domains are of primary 
concern to BC patients: urinary and sexual.19 However, 
the same research stated that there are few HRQL studies 
in BC, due to a lack of standardised instruments of 
assessment.
In recent years, BC-specific PROMs have been devel-
oped. Many focus on a single type of BC or treatment type 
and few have been externally validated or surveyed large 
populations.20–22
A review of BC HRQL research stated that there are 
limitations in this field of work due to the methodology 
used in research, models used and the heterogeneity 
of disease clinical characteristics.23 As such, choosing 
appropriate PROMs to evaluate HRQL in BC patients is 
challenging for researchers and clinicians. The review 
recommended that future research should develop a 
comprehensive model of HRQL, that is, sensitive to 
changes in NMIBC and MIBC.
The majority of BC HRQL research focusses on MIBC 
patients and compares type of urinary diversion.23 Find-
ings showed that regardless of the PROM used, the type 
of urinary diversion is not a consistent predictor of global 
HRQL but can impact on functionality, such as urinary 
function.23 24
Comparatively fewer studies have reported on the 
HRQL of patients with NMIBC. Longitudinal research 
in this area measured the HRQL of 244 NMIBC patients 
treated with transurethral resection of bladder tumour 
(TURBT), with or without intravesical therapy, over a 
year period.25 Over the year urinary function significantly 
improved, bowel function and sexual bother remained 
stable and sexual function decreased. Mental health 
was also found to be statistically lower in patients than 
the control population at baseline and 6 months, before 
improving at 12 months.25
Few large-scale studies of BC (NMIBC and MIBC) 
HRQL have been conducted, with research to date being 
cross-sectional. Research in the USA, of patient’s ≥65 
years old found poorer physical functioning in patients 
with MIBC, persisting for >10 years postdiagnosis.26 Euro-
pean PROMs work with 823 German patients found that 
BC patients in both groups reported poorer emotional 
and physical functioning than in the general popula-
tion.27 Both studies used generic PROMs or generic 
cancer PROMs. The lack of large-scale PROMs research 
in BC is detrimental as it hinders patient pathways and 
patterns of care, limits the accuracy of counselling and 
masks inequalities in care.
study aims
Primary aims
1. To describe the HRQL of patients living with BC diag-
nosed in Yorkshire and the Humber.
2. To gain a deeper understanding of the variation in out-
comes.
3. To identify areas of unmet need.
Secondary aims
1. To develop a PROM tool to collect and interpret data 
from patients with BC diagnosed in Yorkshire and the 
Humber, with a view to extending into a national sur-
vey and ultimately improving clinical care.
2. To explore if and how HRQL is associated with or 
predicted by disease, treatment and/or patient char-
acteristics in Yorkshire and the Humber, with a view 
to informing service delivery in order to better meet 
patient needs.
3. To use PROMs data to understand differences between 
newly diagnosed patients, those undergoing treatment 
and those having completed treatment for BC in York-
shire and the Humber and to compare different treat-
ments and healthcare providers.
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4. To report PROMs results, allowing providers to see the 
responses from their patients and to identify any areas 
of concern.
The study will achieve these aims through 3 work-
streams. The study will collect data from patients diag-
nosed at 15 sites across Yorkshire and the Humber 
providing BC care: Airedale, Barnsley, Bradford, Calder-
dale, Chesterfield, Doncaster, Harrogate, Hull and East 
Yorkshire, Leeds, Mid Yorkshire, North Lincolnshire and 
Goole, Rotherham, Sheffield, South Tees and York.
MEthods And AnAlysIs
The LABC study began in May 2016 and will run until 
30 April 2020.
Patient eligibility
Inclusion criteria for the longitudinal survey:
 ► A new diagnosis of BC with no previous history of the 
disease.
 ► No more than 3 months postdiagnosis at the time of 
identification. Date of diagnosis is taken as the date of 
the first tumour resection (TURBT) with histological 
confirmation of BC.
 ► Able to complete the survey form by themselves or 
with help.
 ► Able to read and understand English.
Inclusion criteria for the cross-sectional survey:
 ► A previous diagnosis of BC within the last 10 years. 
Date of diagnosis is taken as the date of the first 
tumour resection (TURBT) with histological confir-
mation of BC.
 ► Diagnosed by one of the NHS hospitals in Yorkshire 
and the Humber.
 ► Not taking part in the longitudinal study.
 ► Able to complete the survey form by themselves or 
with help.
Exclusion criteria both surveys:
 ► Age under 18 years.
 ► Participants who are prisoners in the custody of HM 
Prison Service with an HMP address.
 ► Lack the capacity to give informed consent—this 
may be due, for example, to psychopathology, cogni-
tive dysfunction or learning difficulties (longitudinal 
survey).
 ► Previous diagnosis of BC (longitudinal survey).
 ► Patients who register type 2 objections (cross-sectional 
survey).28
Workstream 1: ProMs instrument refinement
A survey instrument has been developed that covers a 
range of generic and cancer-specific PROMs that address 
both NMIBC and MIBC populations. The survey will 
also contain items regarding treatments received, socio-
demographic details, lifestyle questions and the patient 
perspective of their disease, treatment, needs and expe-
riences. This content was informed by several factors. 
These include the incorporation of questionnaire 
measures used by colleagues in similar surveys and the 
experiences from these surveys (including response 
rates), the undertaking of a scoping and systematic 
review of PROMs used in BC research, availability of 
routine demographic and health data (to avoid dupli-
cate collection of information), potential literacy issues 
experienced by patients from more deprived areas, 
questionnaire burden, item duplication/redundancy, 
costs and permission, and the priorities of different 
coapplicants and advisory group members, including 
service users were also considered.
Survey measures
Generic HRQL
The included measures are:
1. EuroQol (EQ-5D-5L): this measure records problems 
on five domains; mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression.29
2. Short Warwick-Edinburgh Mental Well-Being Scale 
(SWEMWBS): a positive construct of emotional 
well-being. SWEMWBS is a UK validated shortened, 
7-item version of the Warwick-Edinburgh Mental Well-
Being Scale.30
Cancer-specific and BC-specific
These measures include:
1. European Organisation for Research and Treatment 
of Cancer core questionnaire (EORTC QLQ-C30): full 
questionnaire.31
2. BC-specific module consisting of merging the items 
of EORTC QLQ-BLM30 (MIBC module) and EORTC 
QLQ-NMIBC24 (NMIBC module)21 32 as they share 
a number of items, allowing for patients with both 
NMIBC and MIBC to be surveyed while reducing pa-
tient burden.
3. Social Difficulties Inventory (SDI): this measure was 
developed to assess everyday problems experienced 
by cancer patients.33 Sixteen of the items form three 
subscales: everyday living, money matters and self and 
others. These scales form a measure of social distress.34 
As in previous research, three individual SDI items on 
difficulty with sexual matters (covered in detail else-
where), housing and any other difficulty have been ex-
cluded due to poor endorsement in the pilot work of 
previous research.18
4. Bladder Utility Symptom Scale: a recently developed 
tool consisting of 10 questions and a visual analogue 
scale, designed for use with a variety of BC patients.35
Patient, clinical, lifestyle and sociodemographic characteristics
These include:
1. Treatment items informed by BC clinicians, patients, a 
BC charity support website and experts.
2. Comorbidity item (a list of possible conditions).
3. Standard sociodemographic items informed by the Of-
fice for National Statistics and other sources.
4. Support for previous mental health problems, taken 
from the National Comorbidity Survey.36 37
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5. Item about carer status included in recognition of the 
increasing number of carers.
6. Godin Leisure-Time Exercise Questionnaire,38 com-
prising two items which assess exercise behaviours.
7. Three items about cigarette and e-cigarette use.
8. Two items about employment status relating to em-
ployment status at diagnosis (baseline longitudinal 
survey only), current employment status and sick pay 
received.
Patient perspective measures
The included measures are:
1. Decision Regret Scale39 which provides an indication 
of healthcare postdecision regret at a set moment in 
time.
Cognitive testing of the survey has been carried out 
by the approved survey provider (Quality Health) with a 
group of BC patients. Appropriate revisions were made to 
the surveys.
A summary of the questionnaires included in each 
survey is included in table 1.
Workstream 2: longitudinal ProMs survey
Sample strategy and size
National Cancer Registration and Analysis Service 
(NCRAS) data suggest that there were 1902 new cases of 
BC diagnosed in Yorkshire and the Humber in 2014 and 
that at 1 year postdiagnosis 1283 patients were still alive 
(table 2).
Table 1 Overview of questionnaires included in cross-sectional and longitudinal surveys  
Domains Questionnaires/items
Time points
T1/cross-
sectional T2 T3 T4
Your overall health EQ-5D-5L Yes Yes Yes Yes
Your treatment Treatment items Yes Yes Yes Yes
Decision Regret Scale No No No Yes
How things are for 
you now
EORTC QLQ-C30 Yes Yes No Yes
EORTC merged bladder cancer modules 
(NMIBC24 and BLM30)
Yes Yes No Yes
Bladder Utility Symptom Scale No No Yes No
Your everyday life Social Difficulties Inventory Yes Yes No Yes
Your care needs Supportive Care Needs Survey 34 No No Yes No
Your emotional well-
being
Short Warwick-Edinburgh Mental Well-being 
Scale
Yes Yes No Yes
Your exercise habits Godin-Leisure-Time Exercise Questionnaire 
(prior to diagnosis)
Yes No No No
Godin-Leisure-Time Exercise Questionnaire 
(current)
No No No Yes
Smoking Cigarette smoking Yes No No Yes
E-cigarette smoking Yes No No Yes
Passive smoking Yes No No Yes
About you Age Yes No No No
Marital status Yes No No Yes
Ethnicity Yes No No No
Other conditions (comorbidities) Yes Yes Yes Yes
Height Yes No No No
Weight Yes Yes Yes Yes
Support for mental health or alcohol/drugs Yes No No Yes
Carer Yes No No No
Your employment 
status
Employment (prior to diagnosis) Yes No No No
Employment (current) Yes Yes Yes Yes
Sick leave and sick pay Yes Yes Yes Yes
Total number of questions 114 101 56 108
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Core questionnaire. 
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Recruitment
Local NHS clinical research teams, at the participating 
research sites, will identify potential patients following 
discussion in routine BC multidisciplinary team (MDT) 
meetings and confirm that the patient can be approached 
to take part in the LABC study. After checking the 
patient is eligible, eligible patients will be approached 
by a member of the clinical research team about the 
study. Patients will be given study information and will be 
asked to sign a consent form giving informed consent if 
they wish to take part. Patients giving informed consent 
in person will be asked to complete a participant details 
form.
The participant details form will ask patients to 
complete their contact details and preferred method 
for completing the survey (online, on paper or over 
the telephone). One copy of the signed consent form/
participant details form will be filed by the clinical team. 
Patients will have a copy to keep.
Patients who give informed consent to take part will 
be surveyed at baseline (<3 months after diagnosis) and 
again at 6, 9 and 12 months postdiagnosis.
Patients who could not be approached in person will be 
sent a letter from their MDT lead clinician, inviting them 
to take part. Study documents and two copies of a sheet 
comprising the consent form and participant details 
form will be included with a freepost return envelope. 
The signed consent form/participant details form will be 
returned to the clinical team.
If no consent form has been received within 2 weeks, 
then a member of the clinical research team will contact 
potential participants. The mode of contact will be by 
either telephone or letter, at the discretion of the clinical 
research team.
Information from consenting participants will be sent 
from the clinical sites to Public Health England (PHE) 
by secure NHS email. PHE will store this information and 
forward the information to Quality Health.
Quality Health (acting under an agreed data processor 
contract) will send the data to NHS Digital who will carry 
out a list clean of data to check the vital status of patients, 
identify any patients who have died and provide updated 
address checks for participants requesting posted ques-
tionnaires. Once this has been carried out, NHS Digital 
will send the data back to Quality Health who will send out 
the surveys. Two reminders will be sent to non-responders 
(with additional death checks performed). Details of the 
Table 2 Estimated number of newly diagnosed bladder 
cancer patients and survival 1 year postdiagnosis by study 
site
Sites
No of patients 
diagnosed
No alive at 
1 year
South Tees 46 31
Leeds 228 153
York 204 138
Airedale 89 60
Harrogate 79 54
Calderdale 128 86
Bradford 76 52
Hull and East Yorkshire 208 141
North Lincolnshire and 
Goole
156 105
Mid Yorkshire 200 134
Sheffield 188 127
Doncaster 159 107
Rotherham 92 62
Barnsley 39 25
Chesterfield 10 7
Total 1902 1283
Table 3 Overview of study methodology for longitudinal and cross-sectional cohorts
Longitudinal cohort Cross-sectional cohort
Data source NHS Trusts Cancer registry
Confirmation of diagnosis 
and eligibility
MDT leads at Trusts and local research teams at 
each NHS Trust
Bladder MDT lead
Exclusions <18 years; lack capacity to give informed consent; 
previous diagnosis of bladder cancer; participants 
who are prisoners in the custody of HM Prison 
Service with an HMP address
<18 years; registered a type 2 objection; 
participants who are prisoners in the custody 
of HM Prison Service with an HMP address
Death checks NHS Digital NHS Digital
Type 2 opt out checks N/A NHS Digital
Survey mail-out Quality Health Quality Health
Language English English
Survey dates Starts April 2019 Autumn 2018 to Spring 2019
Estimated potential no of 
patients
1902 4000
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methodology for workstream 2 is summarised in table 3 
and figure 1.
Case report forms
Case report forms (CRFs) will be completed at each recruiting 
centre, for patients who consent to take part in the longitu-
dinal study at baseline and 12 months postdiagnosis. These 
CRF’s will be sent securely to the project coordinator at the 
University of Sheffield using  nhs. net email. These CRFs will 
be used to understand current diagnosis and treatments and 
any scheduled future treatments. This will allow for more 
in-depth interpretation and understanding of the quality of 
life data gained from the surveys. The CRFs will be linked 
to the survey responses using the study identification (ID) 
assigned to the patient.
Workstream 3: cross-sectional ProMs survey
Sample strategy and size
Data from NCRAS suggest there are an estimated 7000 
patients alive in Yorkshire and the Humber with a history of 
BC, including 20% with a >10-year history. We estimate that 
after death checks and exclusions due to type 2 objections 
there will be an estimated 4000 people, who were diag-
nosed with BC up to 10 years ago, eligible to take part in the 
cross-sectional study.
Recruitment
The methodology follows that used by the National 
Colorectal PROMs survey, England 201314 and the LAPCD 
study.18 The study team will write to the chief executive 
and BC MDT lead of each Trust to seek their permission to 
survey people treated by their trust in the last 10 years. Trusts 
will be invited to verify the list of identified patients and filter 
any patients where contact would be inappropriate. For the 
Trusts that agree to take part, NCRAS will extract a list of 
eligible patients and send this to NHS Digital for up-to-date 
address tracing and death checks. Once these checks have 
been completed, the information will be passed on to the 
approved survey provider, Quality Health. Details of the 
methodology for workstream 3 is summarised in table 3 and 
figure 2.
The survey will be sent out with a covering letter from 
the treating NHS Trust’s Chief Executive and MDT lead 
Figure 1 Study data flow for the longitudinal study (workstream 2). NCRAS, National Cancer Registration and Analysis. 
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and a summary and full version of the participant infor-
mation sheet. The covering letter will indicate that the 
survey is only to be completed if the patient has received 
a diagnosis of BC.
Patients who agree to participate will complete and 
return the survey in prepaid freepost envelopes to Quality 
Health. Instructions will be provided to allow patients to 
complete online or over the phone if they wish.
As in the longitudinal survey, no identifying informa-
tion will be included in the surveys but a unique refer-
ence number (URN) will be used to keep track of which 
patients have returned the survey or who have opted out. 
Two reminders will be sent (with additional death checks 
performed).
ProMs completion: written or electronic options
For the longitudinal study, participants will be asked how 
they wish to be contacted, as part of the consent process. 
The options include written (letters), electronic (email 
address) or by telephone (verbal, from Quality Health).
Participants will be allowed to change between modes 
of communication and completion at their discre-
tion. Participants who want to change their method of 
completion will be instructed to contact the study help-
line, who will facilitate this. The survey will be sent out 
either electronically or by post (dependent on which 
option the participant identified as their preferred way to 
complete) with a covering letter from the study principal 
investigators.
People eligible to take part in the cross-sectional survey 
will be a sent a survey pack through the post. The survey 
pack will include a paper copy of the survey, a freepost 
envelope for returning the paper survey, a summary 
patient information sheet (PIS), a full version of the PIS 
(so that they have more details about the study), a covering 
letter and information and instructions for accessing the 
survey online (eg, their unique username and password, 
website address). Participants will be asked to complete 
and return the survey either by post in a provided free-
post envelope, by completing the survey online or over 
Figure 2 Study data flow for the cross-sectional study (workstream 3). CRFs, case report forms; PHE, Public Health England; 
PIS, patient information sheet.   
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the telephone. By completing the survey, the participant 
is consenting to take part in the study.
Paper versions of the survey will include a copy of the 
survey and a freepost envelope in which to return the 
survey to Quality Health. Details of how to complete the 
survey over the telephone will be included in the covering 
letter.
For the online option, a web address (URL) will be 
provided that takes the person to the survey. This infor-
mation will enable them to access the survey online. 
Participants can complete the survey online from any 
internet accessible location, at any time. Completion of 
the online survey will take ~30 minutes, although partic-
ipants can spread-out completion (eg, over a number of 
days) if they wish.
The surveys will not contain any personal information 
(ie, no names or addresses) but will be assigned a URN. 
The URN can be linked back to the consented patients 
to keep track of which participants have returned the 
survey or have opted out (by returning the survey blank 
or phoning the dedicated survey helpline).
Quality Health will send two reminders (with additional 
checks performed each time) to participants taking part 
in the studies, who do not complete the survey. The first 
reminder will be a letter and the second reminder will be 
a full invitation pack.
Quality Health will scan and input data for the completed 
surveys and clean the data, including removing any iden-
tifying information that patients may have provided. The 
cleaned, electronic dataset of pseudonymised survey 
responses will be sent, alongside a study ID number, to 
the research team for analysis.
Freephone helpline
For both the longitudinal and cross-sectional surveys, 
a 24-hour freephone service will be provided during 
periods when the surveys are live. Any queries pertaining 
to BC symptoms or disease management will be directed 
to the Fight Bladder Cancer charity helpline service. 
Fight Bladder Cancer are a UK-based BC charity founded 
and run by BC survivors and families to support people 
impacted by BC, raise awareness of the disease, support 
research and campaign for changes in policy.
For other enquiries, for example, where the patient 
informs the helpline that they do not have cancer or 
that they do not wish to be contacted again, escalation 
processes have been developed (figures 3 and 4). Proce-
dures to rapidly manage and report any incidents arising 
from the survey have been established. It is not possible 
to foresee all possible queries or issues that will arise 
during the study duration. However, processes have been 
developed to deal with issues that have arisen in previous 
PROMs surveys.
data linkage
The survey response data from the cross-sectional study 
will be sent to NCRAS where it will be linked to a number 
of routine data sets in order to maximise the amount of 
clinical and treatment information available. The datasets 
for linkage include:
 ► Cancer registration: these data will provide staging 
information, area-level deprivation, confirmation of 
reported treatments and validation of age, sex and 
ethnicity. Cancer registration data are available for all 
BC patients and can be used to assess responder bias 
(comparison of the respondents and non-respond-
ents in terms of age, deprivation and so on).
 ► Hospital admissions: these data will provide information 
on inpatient and outpatient admissions, including 
treatments received, hospital visited, specialty, length 
of stay and other conditions/comorbidities.
 ► Radiotherapy: these data can provide information on 
type of radiotherapy (long or short course), number 
of fractions, intent and so on.
 ► Chemotherapy: the systemic anticancer therapy dataset 
can provide information on inpatient, day case, 
outpatient and community setting chemotherapy 
treatment.
All linkage will be undertaken by trained staff at 
NCRAS who have approvals to work with identifiable data. 
Linkage will be approved by the Office for Data Release. 
Once linked, the data will be pseudonymised (names, 
addresses, dates of birth, NHS numbers removed) and 
securely transferred to the study team for analysis.
data analysis and reporting
Descriptive statistics will be used to report the survey 
results and describe the health outcomes of people 
with BC who have a variety of stages, grades and treat-
ments. The outcome variables, that is, EQ-5D-5L, EORTC 
QLQ-C30, the merged EORTC BC modules (EORTC 
QLQ-NMIBC24 and EORTC QLQ-BLM30) and SDI, 
will be analysed according to stage/severity of disease, 
treatment type, comorbidity, age, ethnic and sociode-
mographic group (and other relevant variables). These 
descriptive analyses will identify potential relationships of 
interest which can be further investigated.
If sufficient data are collected, regression modelling will 
be used to investigate associations among the different 
variables and to identify statistically and clinically signif-
icant risk factors and predictors of health outcomes. 
In order to be robust, analyses will require appropriate 
adjustment for case mix and other confounding factors.
The longitudinal study will allow measurement of any 
changes in outcomes over time. For example, differ-
ences in EQ-5D scores could be calculated between the 
time points and this would allow assessment of whether 
outcomes improve, decline or remain static. Interpre-
tation is difficult, however, as there is no information 
regarding the individuals’ health before their cancer diag-
nosis. Normative data from the general population will 
be used, where these are available, in order to compare 
the health of people with BC with those in the general 
population and to assess whether their health returns to a 
‘normal’ level over time.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030850 on 17 June 2019. Downloaded from 
9Mason SJ, et al. BMJ Open 2019;9:e030850. doi:10.1136/bmjopen-2019-030850
Open access
New instrument development is not being undertaken as 
part of this work. However, there is the opportunity to explore 
and check the psychometric properties of EORTC QLQ-C30 
as a full psychometric evaluation of this PROM has not been 
undertaken with BC patients. There is also the opportunity 
to explore and check the psychometric properties of newer, 
less well-established questionnaires, particularly the merged 
EORTC BC module questions and to determine the most 
fitting instruments for future BC PROMs work.
Management and oversight
An advisory group will be used to provide expert knowledge 
for study design, interpretation, analysis and reporting. The 
group comprises two service user members plus a number of 
(1) health professionals (2) researchers, with commitment 
to, and detailed expertise, research knowledge and experi-
ence of user concerns and priorities. The advisory group and 
project team will meet every 6 months.
The principal investigators, project manager and 
other relevant team members will have weekly telephone 
meeting to review progress.
Patient and public involvement
A patient representative was involved in the grant 
proposal, research design and choice of outcomes. Two 
patients are members of the study advisory group, contrib-
uting as lay advisors to all aspects of this research project. 
Before finalising the surveys, Quality Health carried out 
cognitive testing of the surveys with patients.
EthICs And dIssEMInAtIon
It is intended that the study will provide detailed infor-
mation about the HRQL of BC patients. These data will 
be used to influence and drive service improvements, 
provide information to both patients and clinical teams 
which will allow them to make informed and appropriate 
Figure 3 Patient query escalation policy for the longitudinal study (workstream 2).
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treatment decisions, to understand the needs of different 
groups of BC patients and encourage service providers 
to have measures in place to pre-empt and support those 
needs should current and future patients have them 
(optimise the provision of support pre-treatment and 
post-treatment) and inform future research. The study 
will also go some way to providing the research with an 
understanding of how useful the PROMs used in the study 
detect changes in HRQL of BC patients and whether they 
should be employed in future research.
The success of this study relies on correctly identi-
fying, consenting and contacting eligible patients without 
causing undue distress, and obtaining a high response 
rate from a representative sample of BC newly diagnosed 
patients and survivors. The study results must be dissemi-
nated widely and effectively to provide maximum impact.
General data protection regulation
There were delays in obtaining all relevant approvals for 
workstreams 2 and 3 due to regulatory changes in the 
European Union (including the UK), where the standard 
for data protection is now the general data protection 
regulation (GDPR) rather than the Data Protection Act 
(1998).
Studies collecting data after 25 May 2018 are required 
to make their research GDPR compliant. GDPR is a regu-
lation on data protection and privacy for all individuals in 
the European Union. Regulations require organisations 
Figure 4 Patient query escalation policy for the cross-sectional study (workstream 3). NCRAS, National Cancer Registration 
and Analysis Service. 
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that are involved in data processing to be lawful, fair 
and transparent when processing or controlling the 
processing of personal data. GDPR requires each activity 
of processing data to have a legal basis under this legisla-
tion. For universities, NHS organisations, research council 
institutes or other public authority, the processing of 
personal data for research should be a ‘task in the public 
interest’. Under GDPR, consent is no longer considered 
the legal basis for processing data.40
It is a requirement of NCRAS/PHE and NHS Digital 
that studies using their data are GDPR compliant. Conse-
quently relevant amendments and additions were made 
to all study documents and published study information 
before workstreams 2 and 3 could be approved. Amend-
ments pertained to how study data would be processed 
and used by all organisations involved in the research. 
The research methodology was not changed as part of 
these amendments. This process may be refined as part 
of future research.
Ethical and safety considerations
The methodology for the longitudinal survey requires 
patients to give their informed consent to take part, and 
explains how patients can withdraw from the study. As 
patients will be recruited as a result of receiving a diag-
nosis of BC and will receive information about the study 
and what will happen if they consent to taking part, there 
should be minimal risk of patients becoming upset or 
angry at being contacted.
The methodology for the cross-sectional survey will 
follow that adopted in previous surveys (LAPCD,18 
colorectal15) where the number of adverse events/symp-
toms was very low. In addition, approval will be sought 
from the treating Trust/MDT and they will be offered the 
chance to check the list of eligible patients and patients 
will be asked to give their informed consent to take part, 
in adherence with GDPR.41 The invitation letter that 
accompanies the survey will inform patients that if they 
did not receive a diagnosis of BC following investigations 
and/or treatment related to their bladder, to return all 
the enclosed documents, using the freepost envelope 
provided and will not be contacted again.
In both the longitudinal and cross-sectional studies, 
death checks will be carried out on a monthly basis 
and these data will be checked prior to survey mail-out; 
however, it must be acknowledged that even with the 
most stringent checks, a small number of individuals 
may have died very close to the time of survey mailing 
and will receive a survey. Despite all of these measures, 
it is not possible to predict the reaction of patients who 
receive a survey, for example, whether patients receiving 
a cross-sectional survey will become angry or upset at 
being contacted. The information accompanying the 
survey has been carefully worded, in a way similar to the 
wording of documents used in the LAPCD study and has 
been checked with the ethics committee in order to opti-
mise positive reactions. In order to deal with any adverse 
events/symptoms, a procedure for rapid and timely 
response to, and support of, affected individuals has been 
developed.
Patients who have raised a type 2 objection
From 29 April 2016, the Secretary of State for Health 
gave directions that required NHS Digital to establish and 
uphold type 2 objection requests expressed by patients. 
A type 2 objection is a request made by a patient. This 
is lodged with a general practitioner (GP) practice and 
indicates that personal identifiable information relating 
to the patient must not be disseminated or published for 
purposes beyond their direct care.42 In the cross-sectional 
study, a subsection of the patients identified by NCRAS 
may have raised a type 2 objection. Prior to mail-out, NHS 
Digital will identify and remove all patients who have 
registered a type 2 objection.
Maximising response rates
Methods will be employed to promote as high of a 
response rate as possible, including sending two reminder 
letters, which has been shown to increase response rates, 
and the option to complete the survey over the phone 
as it is thought that BC patients in deprived areas have 
a lower literacy rate.43 It is known from previous PROMs 
surveys that there tend to be differences in the charac-
teristics of those who do and do not respond, with the 
elderly, ethnic minorities and those from more socio-
economically deprived areas being less likely to partici-
pate. However, particularly for the longitudinal survey we 
expect some patients to drop out of the study over the 
12-month period.
If, after using the methods above, there are differences 
between the responders and non-responders, statistical 
techniques can be used to adjust for variation in partic-
ipation rates.
The use of online surveys will be explored during both 
studies. Response rates will be examined for variation 
by age, and other sociodemographic factors, and to see 
whether response rates can be increased using online 
methods.
dissemination plan
Dissemination of study findings will be undertaken 
through a series of reports, academic papers (open-ac-
cess) and conference presentations. Additionally, all 
findings will be available on the dedicated study website. 
These outputs will provide understanding of key clinical, 
sociodemographic, psychosocial and service/organisa-
tional factors that have an impact on the generic and 
cancer-specific HRQL of BC patients and will also iden-
tify common issues where support, interventions or addi-
tional services are required for different groups of BC 
patients. An electronic report and toolkit will be available 
to key stakeholders to provide detailed anonymised infor-
mation. The toolkit will enable each NHS Trust, Clinical 
Commissioning Group and Strategic Clinical Network to 
visualise the results for their organisation and to compare 
them against the national ‘average’. The study will also 
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test the use of generic, cancer-specific and BC-specific 
PROMs with this patient group and provide feedback 
about how useful these tools are in measuring BC patient 
HRQL.
Participant anonymity
Publications/reports on the study findings will make no 
reference to the identities of the patients who partic-
ipated. When describing the clinical and sociodemo-
graphic characteristics of the sample, care will be taken 
to ensure that, if any values are small numbers, for 
instance, this information does not allow individuals to 
be identified. Access to medical records (outside of those 
who would ordinarily have access) will only be under-
taken with patients’ explicit consent. All study data will 
be stored securely and accessed only by members of the 
research team on a strict need-to-know basis.
data storage and security
All electronic data transfers will be carried out using 
secure mechanisms, with appropriate encryption and 
use of randomly generated strong passwords. Data will be 
stored on secure networks and accessed only by members 
of the research team using discreet passwords. All 
members of staff involved in the study follow the relevant 
codes of practice concerning confidentiality, information 
security management and records management. Policies 
on safeguarding data will be adhered to.
For the period of the study, the pseudonymised longi-
tudinal and cross-sectional survey data will be stored in a 
secure environment at the University of Leeds. The data 
will be accessed by approved members of the research 
team who will adhere to the agreed data security protocol 
and follow the relevant codes of practice concerning confi-
dentiality, information security and records management.
Identifiable data for both workstreams will go to 
NCRAS and they will be the key holders for these data. 
NCRAS will hold the identifiable data for 10 years after 
the study closes. This would allow a clinical review of the 
initial findings to be done, subject to ethical approval and 
future funding, if the study were extended to other areas.
A 10-year data retention policy will be adopted for (1) 
hard-copy data (survey responses) and (2) electronic 
records (held by Quality Health). At the end of the 
study (24 months after the date of the first letter), the 
names and addresses used for the survey mail-out will 
be destroyed and the records retained for longer will be 
identified only by an ID number (with only NCRAS able 
to identify participants). Quality Health is an approved 
NHS provider and has met all the relevant information 
governance and security. Electronic copies will be held on 
secure networks and accessed only by approved members 
of the team. At the end of the study, the electronic survey 
data will be transferred to the Cancer Services Outcomes 
Dataset within NCRAS. This will be held according to the 
information governance arrangements that apply to all 
other datasets held by NCRAS (Section 251 approval to 
hold information on cancer patients).
Contributors JC and AG are the principal investigators. AD and PW are 
coinvestigators. AW is the patient representative and member of the User Advisory 
Group. Together, these authors conceived and designed the study. SJM and SEB 
have contributed to the design and running of the study. AG, JC, PW and SJM 
contributed to the survey design. All authors have contributed to the writing of the 
study protocol and have approved the final version of this manuscript.
Funding This work was supported by Yorkshire Cancer Research (Award reference 
number: S385—The Yorkshire Cancer Research Bladder Cancer Patient Reported 
Outcomes Survey). 
Competing interests None declared. 
Patient consent for publication Not required.
Ethics approval The study has received the following approvals: Yorkshire and 
the Humber—South Yorkshire Research Ethics Committee (17/YH/0095), Health 
Research Authority Confidentiality Advisory Group (17/CAG/0054); Office for 
Data Release (cross-sectional: ODR1718_089, longitudinal: ODR1718_137) and 
NHS Digital Data Access Request Service (cross-sectional: DARS-NIC-129819-
V5P5Z-v2.4, longitudinal: DARS-NIC-194387-K3H5K-v0.12). 
Provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Office for National Statistics. Statistical Bulletin: Cancer Registration 
Statistics, England. 2015 https://www. ons. gov. uk/ peop lepo pula tion 
andc ommunity/ healthandsocialcare/ cond itio nsan ddis eases/ bulletins/ 
canc erre gist rati onst atis tics england/ 2015 (Accessed Jun 2017).
 2. Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of 
bladder cancer: costs and considerations of caring for this disease. 
Eur Urol 2014;66:253–62.
 3. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence 
and Mortality: A Global Overview and Recent Trends. Eur Urol 
2017;71:96–108.
 4. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management 
of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 
update. J Urol 2007;178:2314–30.
 5. Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy 
for muscle-invasive bladder cancer is low among major 
European centres: results of a feasibility questionnaire. Eur Urol 
2012;61:1070–1.
 6. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-
invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 
2017;71:447–61.
 7. Catto JWF, Rosario DJ. The Road to Cystectomy: Who, When and 
Why? EAU Update Series 2005;3:118–28.
 8. Eylert MF, Hounsome LS, Persad RA, et al. Falling bladder cancer 
incidence from 1990 to 2009 is not producing universal mortality 
improvements. J Clin Urol 2014;7:90–8.
 9. Solomon T, Coleman M, Lee V, et al. Geographic Patterns of Cancer 
Survival in England, Patients Followed up to 2012. London: Office for 
National Statistics, 2014.
 10. Black N. Patient reported outcome measures could help transform 
healthcare. BMJ 2013;346:f167.
 11. Department of Health. Equity and excellence: Liberating the NHS, 
2010.
 12. Department of Health. Improving Outcomes: A Strategy for Cancer, 
2011.
 13. Department of Health. The NHS Outcomes Framework 2013/14. 
London, 2013.
 14. Glaser AW, Fraser LK, Corner J, et al. Patient-reported outcomes 
of cancer survivors in England 1-5 years after diagnosis: a cross-
sectional survey. BMJ Open 2013;3:e002317.
 15. Downing A, Morris EJ, Richards M, et al. Health-related quality of 
life after colorectal cancer in England: a patient-reported outcomes 
study of individuals 12 to 36 months after diagnosis. J Clin Oncol 
2015;33:616–24.
 16. Ness AR, Waylen A, Hurley K, et al. Establishing a large prospective 
clinical cohort in people with head and neck cancer as a biomedical 
resource: head and neck 5000. BMC Cancer 2014;14:973.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030850 on 17 June 2019. Downloaded from 
13Mason SJ, et al. BMJ Open 2019;9:e030850. doi:10.1136/bmjopen-2019-030850
Open access
 17. Ness AR, Waylen A, Hurley K, et al. Recruitment, response rates 
and characteristics of 5511 people enrolled in a prospective clinical 
cohort study: head and neck 5000. Clin Otolaryngol 2016;41:804–9.
 18. Downing A, Wright P, Wagland R, et al. Life after prostate cancer 
diagnosis: protocol for a UK-wide patient-reported outcomes study. 
BMJ Open 2016;6:e013555.
 19. Botteman MF, Pashos CL, Hauser RS, et al. Quality of life aspects 
of bladder cancer: a review of the literature. Qual Life Res 
2003;12:675–88.
 20. Anderson CB, Feurer ID, Large MC, et al. Psychometric 
characteristics of a condition-specific, health-related quality-
of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology 
2012;80:77–83.
 21. Blazeby JM, Hall E, Aaronson NK, et al. Validation and reliability 
testing of the EORTC QLQ-NMIBC24 questionnaire module to 
assess patient-reported outcomes in non-muscle-invasive bladder 
cancer. Eur Urol 2014;66:1148–56.
 22. Gerharz EW, Månsson A, Månsson W. Quality of life in patients with 
bladder cancer. Urol Oncol 2005;23:201–7.
 23. Mohamed NE, Gilbert F, Lee CT, et al. Pursuing Quality in the 
Application of Bladder Cancer Quality of Life Research. Bladder 
Cancer 2016;2:139–49.
 24. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related 
quality of life outcomes in bladder cancer patients using the Bladder 
Cancer Index (BCI). Cancer 2007;109:1756–62.
 25. Schmidt S, Francés A, Lorente Garin JA, et al. Quality of life in 
patients with non-muscle-invasive bladder cancer: one-year results 
of a multicentre prospective cohort study. Urol Oncol 2015;33:19.
e7–19.e15.
 26. Fung C, Pandya C, Guancial E, et al. Impact of bladder cancer 
on health related quality of life in 1,476 older Americans: a cross-
sectional study. J Urol 2014;192:690–5.
 27. Singer S, Ziegler C, Schwalenberg T, et al. Quality of life in patients 
with muscle invasive and non-muscle invasive bladder cancer. 
Support Care Cancer 2013;21:1383–93.
 28. NHS Digital. Patient objections (type 2) Directions. 2016 https:// 
digital. nhs. uk/ about- nhs- digital/ corporate- information- and- 
documents/ directions- and- data- provision- notices/ secretary- of- state- 
directions/ patient- objections- type- 2- directions- 2016 (Accessed Mar 
2019).
 29. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary 
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 
Res 2011;20:1727–36.
 30. Stewart-Brown S, Tennant A, Tennant R, et al. Internal construct 
validity of the Warwick-Edinburgh Mental Well-being Scale 
(WEMWBS): a Rasch analysis using data from the Scottish Health 
Education Population Survey. Health Qual Life Outcomes 2009;7:15.
 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85:365–76.
 32. European Organisation for the Research and Treament of Cancer. 
EORTC Quality of Life. Bladder Cancer: EORTC QLQ-NMIBC24, 
EORTC QLQ-BLM30. http:// groups. eortc. be/ qol/ bladder- cancer- 
eortc- qlq- nmibc24- eortc- qlq- blm30.
 33. Wright EP, Kiely M, Johnston C, et al. Development and evaluation 
of an instrument to assess social difficulties in routine oncology 
practice. Qual Life Res 2005;14:373–86.
 34. Wright P, Smith A, Roberts K, et al. Screening for social difficulties in 
cancer patients: clinical utility of the Social Difficulties Inventory. Br J 
Cancer 2007;97:1063–70.
 35. Perlis N, Krahn M, Alibhai S, et al. MP15-01 DEVELOPING THE 
BLADDER UTILITY SYMPTOM SCALE: A MULTIATTRIBUTE 
HEALTH STATE CLASSIFICATION FOR BLADDER CANCER. J Urol 
2014;191:E144–E44.
 36. Kessler RC, Davis CG, Kendler KS. Childhood adversity and adult 
psychiatric disorder in the US National Comorbidity Survey. Psychol 
Med 1997;27:1101–19.
 37. Cougle JR, Timpano KR, Sachs-Ericsson N, et al. Examining the 
unique relationships between anxiety disorders and childhood 
physical and sexual abuse in the National Comorbidity Survey-
Replication. Psychiatry Res 2010;177(1-2):150–5.
 38. Godin G, Shephard RJ. A simple method to assess exercise behavior 
in the community. Can J Appl Sport Sci 1985;10:141–6.
 39. Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision 
regret scale. Med Decis Making 2003;23:281–92.
 40. NHS Health Research Authority. GDPR guidance for researchers 
and study coordinators. 2018 https://www. hra. nhs. uk/ planning- and- 
improving- research/ policies- standards- legislation/ data- protection- 
and- information- governance/ gdpr- guidance/ (Accessed May 2018).
 41. Information Commisioners Office. Consultation: GDPR consent 
guidance, 2017.
 42. NHS Digital. Opting out of sharing your confidential patient 
information. 2019 https:// digital. nhs. uk/ about- nhs- digital/ our- work/ 
keeping- patient- data- safe/ how- we- look- after- your- health- and- care- 
information/ your- information- choices/ opting- out- of- sharing- your- 
confidential- patient- information (Accessed Mar 2019).
 43. European Association of Urology Nurses. Health illiteracy in 
urological patients. 2019 https:// nurses. uroweb. org/ health- illiteracy- 
in- urological- patients/ (Accessed Mar 2019).
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030850 on 17 June 2019. Downloaded from 
